Research Agreements in Ovarian and Liver Cancer

RNS Number : 0679D

Oncimmune Holdings PLC

04 July 2016

 

PRESS RELEASE                                                                                               4 July 2016

Oncimmune Signs Research Agreements in Ovarian and Liver Cancer

Samples Sourced to Validate EarlyCDT® in New Indications

Nottingham, UK - 4 July 2016: Oncimmune Holdings plc (AIM: ONC.L) ("Oncimmune" or the "Company" or the "Group"), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, announces that is has signed research agreements with Egybiotech, a private research company with a broad research portfolio in the areas of cancer research, and Aarhus University Hospital ("Aarhus"), Denmark.

Under these agreements, Egybiotech and Aarhus provide Oncimmune with prospectively collected blood samples and associated clinical data on each patient in order to further clinically validate the Company's EarlyCDT® platform technology in liver and ovarian cancer, respectively. Oncimmune will use the samples to validate panels of autoantibodies as diagnostic tests capable of distinguishing between malignant and non-malignant liver and ovarian diseases, particularly at an early stage.

Geoffrey Hamilton-Fairley, CEO of Oncimmune commented: "Current biomarkers for liver and ovarian cancer perform poorly and our EarlyCDT® technology has the potential to allow earlier diagnosis of these serious diseases and improve patient outcomes. The agreements are a significant further step in the final clinical validation of EarlyCDT® liver and ovarian and will enable us to remain on track towards the goal of launching the tests commercially in 2017. "

About Oncimmune

Oncimmune is a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company's first product, EarlyCDT®-Lung, was launched in 2012, as a CLIA test in the USA and since then over 140,000 commercial tests have been sold. EarlyCDT®-Lung is available through physicians in the US and also privately in the UK and other regions. EarlyCDT®-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,000 high-risk smokers. EarlyCDT® tests for liver and ovarian cancer are in development.

Oncimmune, headquartered in Nottingham, United Kingdom with testing facilities in the US, joined AIM in May 2016 under the ticker ONC.L. For more information visit www.oncimmune.com

For further information:

Oncimmune Holdings plc

Geoffrey Hamilton-Fairley, Chief Executive Officer

[e-mail]

Zeus Capital Limited (Nominated Adviser and Broker)

Phil Walker, Andrew Jones, Dominic Wilson

[phone]

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey Neville

[e-mail]

[phone]

 

END

 

 

NRAGMGGNMFZGVZZ